Articles tagged with “anti-cd38-therapy”

Sarclisa SC PDUFA Delay & Multiple Myeloma OBI Strategy

Analyze the FDA's three-month PDUFA delay for subcutaneous Sarclisa. Examine its on-body injector technology, clinical data, and anti-CD38 competitors.

35 min read

5/13/2026

sarclisa sc isatuximab on-body injector multiple myeloma anti-cd38 therapy pdufa delay subcutaneous formulation